Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab in Combination With Cisplatin and 5-Fluorouracil as Induction Therapy in Children and Adults With EBV-positive Nasopharyngeal Carcinoma

NCT06019130 is registered in ClinicalTrials.gov with German Society for Pediatric Oncology and Hematology GPOH gGmbH as lead sponsor.

NCT NCT06019130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06019130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab in Combination With Cisplatin and 5-Fluorouracil as Induction Therapy in Children and Adults With EBV-positive Nasopharyngeal Carcinoma
Lead sponsor
German Society for Pediatric Oncology and Hematology GPOH gGmbH
Phase
Phase 2
Overall status
Recruiting
Start date
January 10, 2023
Completion date
January 9, 2028
Enrollment
57 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal cancer, nasopharyngeal carcinoma, nasopharyngeal neoplasms, nasopharynx cancer